NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry

Area of Science:

• Radiochemistry and Nuclear Medicine
• Oncology
• Materials Science

Background:

• Effective molecular imaging and targeted cancer therapy require metabolically stable, kinetically inert, receptor-specific delivery systems.
• Current metal complexing agents lack the versatility to coordinate diverse metals while maintaining the kinetic inertness needed for clinical theranostics.
• Minimizing unintended radioactivity accumulation in non-target tissues necessitates enhanced in vivo kinetic stability of radiolabeled compounds.

Purpose of the Study:

• To review the utility of NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and its derivatives as versatile metal complexing agents.
• To highlight the development of NOTA-based conjugates for improved in vivo kinetic stability and reduced demetallation.
• To discuss the design of NOTA-based small molecules targeting Gastrin-Releasing Peptide Receptor (GRPR), Somatostatin Receptor Subtype 2 (SSTR2), and Melanocortin-1 Receptor (MC1R) for cancer therapy.

Main Methods:

• Review of literature on NOTA and its derivatives in radiometal coordination.
• Analysis of NOTA's ability to form stable complexes with various radiometals, including metal-radiohalogens.
• Discussion of the design principles for NOTA-based small molecule and peptide conjugates targeting specific cancer receptors.

Main Results:

• NOTA and its derivatives effectively coordinate a wide range of radiometals, forming stable complexes.
• NOTA-based conjugates demonstrate potential for resisting in vivo demetallation, crucial for theranostic applications.
• Development of NOTA-based small molecules with high affinity and selectivity for GRPR, SSTR2, and MC1R, receptors prevalent on solid tumors.

Conclusions:

• NOTA derivatives represent a versatile platform for developing kinetically inert radiometal complexes for targeted cancer therapy and molecular imaging.
• The enhanced stability of NOTA-based conjugates minimizes off-target radionuclide accumulation, improving therapeutic efficacy and safety.
• NOTA-based targeting agents show significant promise for clinical applications in diagnosing and treating various solid tumors expressing GRPR, SSTR2, or MC1R.